Rhythm Pharmaceuticals, Inc.
500 Boylston Street, 11th Floor
Boston, MA 02116
June 18, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Dorrie Yale
Re: Rhythm Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-225700)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-225700) (the “Registration Statement”) of Rhythm Pharmaceuticals, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 5:10 p.m., Eastern time, on June 20, 2018, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling Laurie Cerveny at (617) 951-8527.
[Remainder of page intentionally left blank]
| Very truly yours, | |
|
| |
| Rhythm Pharmaceuticals, Inc. | |
|
| |
| By: | /s/ Keith M. Gottesdiener |
|
| Keith M. Gottesdiener, |
|
| Chief Executive Officer and President |
CC: | Hunter Smith, Rhythm Pharmaceuticals, Inc. |
| Julio Vega, Morgan, Lewis & Bockius LLP |
| Laurie A Cerveny, Morgan, Lewis & Bockius LLP |
| Patrick O’Brien, Ropes & Gray LLP |
| Thomas Danielski, Ropes & Gray LLP |
[Rhythm Pharmaceuticals, Inc. — Signature Page to Request for Acceleration]
